Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 78


Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.

Morrow PK, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M, Schmelter T, Wang Y, Hortobagyi GN, Vahdat LT.

Breast Cancer Res Treat. 2010 Oct;123(3):837-42. doi: 10.1007/s10549-010-1102-x. Epub 2010 Aug 10.


A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.

Rustin G, Reed N, Jayson GC, Ledermann JA, Adams M, Perren T, Poole C, Lind M, Persic M, Essapen S, Gore M, Calvert H, Stredder C, Wagner A, Giurescu M, Kaye S.

Ann Oncol. 2011 Nov;22(11):2411-6. doi: 10.1093/annonc/mdq780. Epub 2011 Mar 3.


A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.

Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, Krop IE, Partridge AH, Eisenberg E, Winer EP, Lin NU.

Clin Breast Cancer. 2011 Dec;11(6):376-83. doi: 10.1016/j.clbc.2011.03.024. Epub 2011 Jun 22.


Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.

Heigener DF, von Pawel J, Eschbach C, Brune A, Schmittel A, Schmelter T, Reck M, Fischer JR.

Lung Cancer. 2013 Jun;80(3):319-25. doi: 10.1016/j.lungcan.2013.02.007. Epub 2013 Mar 20.


Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.

McMeekin S, Patel R, Verschraegen C, Celano P, Burke J 2nd, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y, Schmelter T.

Br J Cancer. 2012 Jan 3;106(1):70-6. doi: 10.1038/bjc.2011.499. Epub 2011 Nov 22.


Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.

Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H, Thiel E, Kühnhardt D.

Ann Oncol. 2010 Mar;21(3):633-9. doi: 10.1093/annonc/mdp491. Epub 2009 Oct 30.


Sagopilone, a microtubule stabilizer for the potential treatment of cancer.

Galmarini CM.

Curr Opin Investig Drugs. 2009 Dec;10(12):1359-71. Review.


Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.

Arnold D, Voigt W, Kiewe P, Behrmann C, Lindemann S, Reif S, Wiesinger H, Giurescu M, Thiel E, Schmoll HJ.

Br J Cancer. 2009 Oct 20;101(8):1241-7. doi: 10.1038/sj.bjc.6605327. Epub 2009 Sep 22.


Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.

Stupp R, Tosoni A, Bromberg JE, Hau P, Campone M, Gijtenbeek J, Frenay M, Breimer L, Wiesinger H, Allgeier A, van den Bent MJ, Bogdahn U, van der Graaf W, Yun HJ, Gorlia T, Lacombe D, Brandes AA.

Ann Oncol. 2011 Sep;22(9):2144-9. doi: 10.1093/annonc/mdq729. Epub 2011 Feb 14.


Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.

Diéras V, Limentani S, Romieu G, Tubiana-Hulin M, Lortholary A, Kaufman P, Girre V, Besenval M, Valero V.

Ann Oncol. 2008 Jul;19(7):1255-60. doi: 10.1093/annonc/mdn060. Epub 2008 Apr 1.


Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M.

J Clin Oncol. 2007 Aug 10;25(23):3399-406. Epub 2007 Jul 2.


Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.

Silvani A, Gaviani P, Fiumani A, Scaioli V, Lamperti E, Eoli M, Botturi A, Salmaggi A.

J Neurooncol. 2009 Oct;95(1):61-4. doi: 10.1007/s11060-009-9890-8. Epub 2009 Apr 21.


Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, Roth K, Wang Y.

Br J Cancer. 2012 Aug 21;107(5):808-13. doi: 10.1038/bjc.2012.339. Epub 2012 Jul 31.


Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

Roché H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Curé H.

J Clin Oncol. 2007 Aug 10;25(23):3415-20. Epub 2007 Jul 2.


Lapatinib and ixabepilone for the treatment of metastatic breast cancer.

Halterman PA.

Pharmacotherapy. 2008 Oct;28(10):1255-66. doi: 10.1592/phco.28.10.1255. Review.


Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer.

Gauler TC, Christoph DC, Fischer J, Frickhofen N, Huber R, Gonschorek C, Roth K, Giurescu M, Eberhardt WE.

Eur J Cancer. 2013 Jul;49(11):2461-8. doi: 10.1016/j.ejca.2013.03.029. Epub 2013 May 18.


Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.

Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M.

J Clin Oncol. 2002 May 15;20(10):2551-8.


First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors.

Araki K, Kitagawa K, Mukai H, Mukohara T, Kodama K, Ando Y, Narabayashi M, Minami H, Mera K, Sasaki Y.

Invest New Drugs. 2012 Dec;30(6):2327-33. doi: 10.1007/s10637-011-9773-7. Epub 2011 Dec 4.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk